A phase I/Ib open-label, first-in-human, single agent, dose escalation and expansion study of a HER2-targeted T cell engager (SAR443216) in patients with relapsed/refractory HER2-expressing solid tumors

被引：2

作者：

Dumbrava, E. E. ^{[1
]}

Calvo, E. ^{[2
]}

Garralda, E. ^{[3
]}

Ryu, M. H. ^{[4
]}

Oh, D. Y. ^{[5
]}

Bai, L. Y. ^{[6
,7
]}

Chung, W. ^{[8
]}

Rojas Laimito, K. I. ^{[9
]}

Yildirim, O. ^{[9
]}

Masciari, S. ^{[10
]}

Kang, K. ^{[11
]}

Buday, B. ^{[12
]}

Rharbaoui, F. ^{[13
]}

Abbadessa, G. ^{[14
]}

Moreno Garcia, V. ^{[15
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX USA

[2] START Madrid CIOCC, Div Med Oncol, Ctr Integral Oncol Clara Campal, Madrid, Spain

[3] Hosp Valle De Hebron, Early Drug Dev Grp, Barcelona, Spain

[4] Univ Ulsan, Coll Med, Dept Oncol, Asan Med Ctr, Seoul, South Korea

[5] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[6] China Med Univ Hosp, Div Hematol & Oncol, Taichung, Taiwan

[7] China Med Univ, Taichung, Taiwan

[8] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Dept Med Oncol, Coll Med, Tainan, Taiwan

[9] Sanofi, Oncol Early Dev Scientists, Cambridge, MA USA

[10] Sanofi, Early Dev, Cambridge, MA USA

[11] Sanofi, Biostat Oncol Early Dev, Cambridge, MA USA

[12] Sanofi, PV Oncol, Budapest, Hungary

[13] Sanofi, Pharmacokinet Pharmacodynam, Frankfurt, Germany

[14] Sanofi, Oncol Dev, Cambridge, MA USA

[15] Hosp Fdn Jimenez Diaz, START Madrid FJD, Oncol, Madrid, Spain

来源：

关键词：

D O I：

10.1016/j.annonc.2023.09.2214

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1075TiP

引用

页码：S647 / S647

页数：1